Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Visceral Pain Market Growth in 2025?

The market size for visceral pain has seen robust growth in the recent past. The market is slated to expand from $13.84 billion in 2024 to $14.87 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors such as an aging demographic, surging prevalence of chronic ailments, progress in medical investigations, improvement of healthcare amenities, and enhancing awareness and detection rates have contributed to the growth during the historical period.

What Is the Forecast for the Visceral Pain Market Size Through 2029?

The market for visceral pain is projected to experience significant growth in the upcoming years, with expectations of reaching a value of $18.71 billion in 2029, with a 5.9% Compound Annual Growth Rate (CAGR). The predicted growth in this period can be ascribed to factors such as advancements in pain management technology, an increase in demand for non-invasive treatments, the emergence of new markets and untapped potential, approaches that focus on personalized medicine, as well as the incorporation of digital health solutions. Key trends noted for the forecast period are a transition towards multimodal pain management, a heightened focus on alternative therapies, the upsurge of targeted therapies for specific pain forms, an expanded role of telemedicine in managing pain, and the integration of AI in evaluating pain.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13950&type=smp

What are the Key Market Players in Visceral Pain Market and How They’re Evolving?

Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

What Are the Primary Growth Drivers in the Visceral Pain Market?

The visceral pain market is expected to experience growth as a result of the increasing use of analgesics. These medicines, which work by decreasing or blocking the perception of pain signals in the brain, are crucial in the management of visceral pain. They achieve this by focusing on the nervous system and modulating pain signals that come from the internal organs. A key signal for this was in April 2024, when the New England Journal of Medicine reported that over 53,600 clinicians in the UK had prescribed buprenorphine by the end of December 2023. This marked an increase of 11,500 prescribers from the same period in 2022. Consequently, the increased use of analgesics is driving expansion in the visceral pain market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13950&type=smp

What Are the Leading Segments in the Global Visceral Pain Industry?

The visceral pain market covered in this report is segmented –

1) By Drug Class: Calcium Channel Blockers, Nonsteroidal Anti-Inflammatory (NSAID), Other Drug Classes

2) By Indications: Interstitial Cystitis, Crohn’s, Irritable Bowel, Chronic Prostatitis, Other Indications

3) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAID): Selective COX-2 Inhibitors, Non-Selective NSAIDs

3) By Other Drug Classes: Opioids, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

What Are the Key Market Trends in the Visceral Pain Industry?

In the visceral pain market, prominent companies are venturing into the creation of innovative solutions, such as NHE3 Inhibitor, in an effort to offer trustworthy services to their clients. NHE3 inhibitors are drugs that function by restraining the Sodium-Proton-Exchanger subtype 3 (NHE3) in the intestines. For instance, Ardelyx, an American biopharmaceutical enterprise, introduced the NHE3 Inhibitor medication, IBSRELA, in April 2022. IBSRELA is an innovative treatment designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and operates by suppressing the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. In animal trials, it has displayed a reduction in abdominal discomfort by lessening visceral hypersensitivity and intestinal permeability.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report

What Is the Regional Outlook for the Visceral Pain Market?

North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13950

This Report Delivers Insight On:

1. How big is the visceral pain market, and how is it changing globally?

2. Who are the major companies in the visceral pain market, and how are they performing?

3. What are the key opportunities and risks in the visceral pain market right now?

4. Which products or customer segments are growing the most in the visceral pain market?

5. What factors are helping or slowing down the growth of the visceral pain market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model